Labroots: ACE CancerPlus Test for DNA & RNA Sequencing for Improved Patient Outcomes Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and interpretation company, has developed a tumor-profiling test that provides clinicians with accurate and comprehensive analysis [...]
Labroots: Benefits & Burdens of Assaying Matched Normal Tissue when Sequencing Cancer Genomes Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses analytical challenges. Recent studies have indicated that jointly analyzing a tumor with its matched normal can [...]
Introduction to Personalis
NGS-based Tumor Profiling: Lab, Clinic & Patient Perspectives This presentation covers comprehensive tumor characterization solutions for clinical trials, cancer research and immune-oncology, including: specific challenges in sequencing and analyzing tumors for neoantigen identification; key differentiators of the ACE IThree speakers from NSGC’s Annual Education Conference 2016 present key challenges associated with NGS-based tumor [...]
Tumor Characterization Solutions for Clinical Trials, Cancer Research & Immuno-Oncology This presentation covers comprehensive tumor characterization solutions for clinical trials, cancer research and immune-oncology, including: specific challenges in sequencing and analyzing tumors for neoantigen identification; key differentiators of the ACE ImmunoID as compared to standard NGS offerings; and a review of the technical [...]
NGS Best Practices for Developing Personalized Neoantigen Vaccines Precision medicine strategies have changed how the industry is approaching the development of cancer treatment vaccines, from targeting tumor-specific mutations to harnessing the power of the immune system. Advances in immuno-oncology research and next-generation sequencing (NGS) technologies has led to the discovery of a promising [...]
Labroots: Precision Genomics and Precision Medicine for Immuno Oncology Tumors often evade immune destruction by adapting and circumventing immune checkpoints to create resistance. This adaptive immunity can be reversed to stimulate the endogenous immune response. Extensive efforts using Immunotherapeutic approaches are currently being investigated for various cancer types to activate our immune system, [...]
Improper sample fixation is a barrier to unlocking the full potential of your precious samples.
Find the answers to the most complex biological questions, with augmented NGS Find the answers to the most complex biological questions, with augmented NGS Finding the answers to complex biological questions, requires a deeper understanding of cancer biology. Personalis ACE Cancer Exome and ACE Cancer Transcriptome features augmented DNA and RNA sequencing for [...]
Unlocking the potential of personalized neoantigen vaccines with ACE ImmunoID™ Cancer vaccine success has been limited, but neoantigen cancer vaccines are demonstrating considerable potential. Learn more about how Personalis can help you to accurately detect neoantigens to enable the development of safer, more effective vaccines.